Pfizer Seeks Full FDA Approval for its COVID-19 Vaccine
Pfizer’s COVID-19 vaccine received Emergency Use Authorization (EAU) from the United States Food and Drug Administration (FDA) in December 2020. Now it is seeking to transition from the EAU to full approval. The two-shot immunization has been widely administered in the US since it first received the EAU and is credited for helping reduce the number of COVID-19 cases as well as morbidity and mortality due to the novel coronavirus. Pfizer submitted its application for full approval on May 7, and the process is estimated to take several months. If the Pfizer vaccine receives full approval from the FDA, it can be marketed directly to consumers, and it may encourage those who are eligible but have yet to be vaccinated to roll up their sleeves. Click here to read more.